| 1. |
中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專委會, 《玻璃體切割手術治療2型糖尿病視網膜病變專家共識》專家組. 玻璃體切割手術治療2型糖尿病視網膜病變專家共識[J]. 中華眼底病雜志, 2024, 40(9): 663-686. DOI: 10.3760/cma.j.cn511434-20240729-00286.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Committee of Ophthalmologist Branch of Chinese Medical Doctor Association, Expert Group of Expert Consensus for Pars Plana Vitrectomy Treatment of Type 2 Diabetic Retinopathy. Expert consensus for pars plana vitrectomy treatment of type 2 diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2024, 40(9): 663-686. DOI: 10.3760/cma.j.cn511434-20240729-00286.
|
| 2. |
Yang CM, Yeh PT, Cheng SF, et al. Macular appearance after diabetic vitrectomy for fibrovascular proliferation: an optical coherence tomography study[J]. Acta Ophthalmologica, 2010, 88(2): 193-198. DOI: 10.1111/j.1755-3768.2008.01420.x.
|
| 3. |
王貝貝, 李秋明, 董淑倩, 等. 玻璃體切除術后黃斑水腫的治療[J]. 國際眼科縱覽, 2019, 43(6): 366-372. DOI: 10.3760/cma.j.issn.1673-5803.2019.06.002.Wang BB, Li QM, Dong SQ, et al. Treatment of macular edema after vitrectomy[J]. Int Rev Ophthalmol, 2019, 43(6): 366-372. DOI: 10.3760/cma.j.issn.1673-5803.2019.06.002.
|
| 4. |
龔軼, 邵彥, 李筱榮. 抗血管內皮生長因子藥物治療糖尿病黃斑水腫臨床試驗的研究與進展[J]. 中華眼底病雜志, 2022, 38(1): 66-71. DOI: 10.3760/cma.j.cn511434-20210524-00268.Gong Y, Shao Y, Li XR. Research and progress in clinical trials of anti-vascular endothelial growth factor drugs in the treatment of diabetic macular edema[J]. Chin J Ocul Fundus Dis, 2022, 38(1): 66-71. DOI: 10.3760/cma.j.cn511434-20210524-00268.
|
| 5. |
Smith JM, Steel DHW. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2015, 2015(8): CD008214[2015-08-07]. https://pubmed.ncbi.nlm.nih.gov/26250103/. DOI: 10.1002/14651858.CD008214.pub3.
|
| 6. |
中華醫學會內分泌學分會. 胰源性糖尿病診斷與治療中國專家共識(2025版)[J]. 中華胰腺病雜志, 2025, 25(6): 401-417. DOI: 10.3760/cma.j.cn115791-20250827-00436-1.Chinese Endocrinology Society. Expert consensus on the diagnosis and treatment of pancreatogenic diabetes in China (2025 edition)[J]. Chin J Pancreatol, 2025, 25(6): 401-417. DOI: 10.3760/cma.j.cn115791-20250827-00436-1.
|
| 7. |
Chauhan MZ, Rather PA, Samarah SM, et al. Current and novel therapeutic approaches for treatment of diabetic macular edema[J/OL]. Cells, 2022, 11(12): 1950[2022-06-17]. https://pubmed.ncbi.nlm.nih.gov/35741079/. DOI: 10.3390/cells11121950.
|
| 8. |
Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management[J]. Indian J Ophthalmol, 2018, 66(12): 1736-1750. DOI: 10.4103/ijo.IJO_1240_18.
|
| 9. |
秦時月, 徐國旭, 張敬法. 炎癥因素在糖尿病性黃斑水腫中的作用及展望[J]. 國際眼科雜志, 2022, 22(8): 1281-1287. DOI: 10.3980/j.issn.1672-5123.2022.8.09.Qin SY, Xu GX, Zhang JF. Roles and perspectives of inflammatory factors in diabetic macular edema[J]. Int Eye Sci, 2022, 22(8): 1281-1287. DOI: 10.3980/j.issn.1672-5123.2022.8.09.
|
| 10. |
Bandello F, Preziosa C, Querques G, et al. Update of intravitreal steroids for the treatment of diabetic macular edema[J]. Ophthalmic Res, 2014, 52(2): 89-96. DOI: 10.1159/000362764.
|
| 11. |
關禹博, 陳松, 趙秉水. 83例硅油取出時機及并發癥的臨床分析[J]. 中國實用眼科雜志, 2004, 22(2): 125-127. DOI: 10.3760/cma.j.issn.1006-4443.2004.02.014.Guan YB, Chen S, Zhao BS. Clinical analysis of the timing of silicone oil removal and complications in 83 cases[J]. Chin J Pract Ophthalmol, 2004, 22(2): 125-127. DOI: 10.3760/cma.j.issn.1006-4443.2004.02.014.
|
| 12. |
滕學龍, 賈志旸, 馬景學. 長期硅油填充眼的眼部并發癥及取出原則[J]. 眼科新進展, 2006, 26(5): 377-379. DOI: 10.3969/j.issn.1003-5141.2006.05.018.Teng XL, Jia ZY, Ma JX. Ocular complications after long-term intraocular silicone tamponade and the principle of its removal[J]. Rec Adv Ophthalmol, 2006, 26(5): 377-379. DOI: 10.3969/j.issn.1003-5141.2006.05.018.
|
| 13. |
姚騰騰, 楊源, 王藝曉, 等. 康柏西普不同給藥方式在玻璃體切割兔眼中的藥物代謝動力學研究[J]. 中華眼視光學與視覺科學雜志, 2025, 27(8): 569-576. DOI: 10.3760/cma.j.cn115909-20250406-00115.Yao TT, Yang Y, Wang YX, et al. Pharmacokinetics of conbercept by different methods of administration in vitrectomized rabbit eyes[J]. Chin J Ophthalmol Vis Sci, 2025, 27(8): 569-576. DOI: 10.3760/cma.j.cn115909-20250406-00115.
|
| 14. |
仇蕊倩, 高自清. OCTA評估視網膜脫離行玻璃體切除聯合硅油填充后黃斑區和視盤區血流變化[J]. 臨床眼科雜志, 2023, 31(3): 215-218. DOI: 10.3969/j.issn.1006-8422.2023.03.006.Qiu RQ, Gao ZQ. OCTA evaluated the blood flow changes in macular area and optic disc area after vitrectomy and silicone oil filling for retinal detachment[J]. J Clin Ophthalmol, 2023, 31(3): 215-218. DOI: 10.3969/j.issn.1006-8422.2023.03.006.
|
| 15. |
張英楠, 陳曉隆. 玻璃體切割術對PDR患者黃斑區視網膜結構及功能的影響[J]. 國際眼科雜志, 2012, 12(2): 235-238. DOI: 10.3969/j.issn.1672-5123.2012.02.13.Zhang YN, Chen XL. Effect of vitrectomy on retinal structure and function in macular area of patients with PDR[J]. Int Eye Sci, 2012, 12(2): 235-238. DOI: 10.3969/j.issn.1672-5123.2012.02.13.
|
| 16. |
柯喜宣, 李翠連, 陳浩宇. 硅油取出聯合玻璃體腔注射曲安奈德治療硅油眼合并黃斑水腫的效果觀察[J]. 中華眼外傷職業眼病雜志, 2024, 46(1): 59-62. DOI: 10.3760/cma.j.cn116022-20230630-00213.Ke XX, Li CL, Chen HY. Observation on the efficacy of silicone oil removal combined with intravitreal injection of triamcinolone acetonide for the treatment of macular edema in eyes with silicone oil tamponade[J]. Chin J Ocul Traum Occupat Eye Dis, 2024, 46(1): 59-62. DOI: 10.3760/cma.j.cn116022-20230630-00213.
|
| 17. |
Lo DM, Flaxel CJ, Fawzi AA. Macular effects of silicone oil tamponade: optical coherence tomography findings during and after silicone oil removal[J]. Curr Eye Res, 2017, 42(1): 98-103. DOI: 10.3109/02713683.2016.1146776.
|
| 18. |
Hsu CR, Hsieh YT, Yang CM, et al. Single-dose effect of intravitreal dexamethasone implant for post-vitrectomy macular edema under silicone oil[J]. Ocul Immunol Inflamm, 2023, 31(8): 1587-1593. DOI: 10.1080/09273948.2021.1970779.
|
| 19. |
Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells[J]. Eur J Pharmacol, 1998, 341(2-3): 309-315. DOI: 10.1016/s0014-2999(97)01464-7.
|
| 20. |
Yolcu ü, Tas A, Ilhan A, et al. Re: Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function[J/OL]. Retina, 2015, 35(3): e24-e25[2015-03-01]. https://pubmed.ncbi.nlm.nih.gov/25699509/. DOI: 10.1097/IAE.0000000000000567.
|
| 21. |
田景毅, 董曉光, 陳楠. 地塞米松加強體外培養的大鼠視網膜血管內皮細胞間的緊密連接[J]. 中華眼科雜志, 2007, 43(7): 646-650. DOI: 10.3760/j.issn:0412-4081.2007.07.015.Tian JY, Dong XG, Chen N. Dexamethasone intensify the tight junctions in rat retinal vascular endothelial cells in vitro[J]. Chin J Ophthalmol, 2007, 43(7): 646-650. DOI: 10.3760/j.issn:0412-4081.2007.07.015.
|
| 22. |
Chin HS, Park TS, Moon YS, et al. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes[J]. Retina, 2005, 25(5): 556-560. DOI: 10.1097/00006982-200507000-00002.
|
| 23. |
Christoforidis JB, Williams MM, Wang J, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy[J]. Retina, 2013, 33(5): 946-952. DOI: 10.1097/IAE.0b013e3182753b12.
|
| 24. |
Niwa Y, Kakinoki M, Sawada T, et al. Ranibizumab and Aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes[J]. Invest Ophthalmol Vis Sci, 2015, 56(11): 6501-6505. DOI: 10.1167/iovs.15-17279.
|
| 25. |
Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes[J]. Invest Ophthalmol Vis Sci, 2011, 52(7): 4605-4609. DOI: 10.1167/iovs.10-6387.
|
| 26. |
Medeiros MD, Alkabes M, Navarro R, et al. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema[J]. J Ocul Pharmacol Ther, 2014, 30(9): 709-716. DOI: 10.1089/jop.2014.0010.
|
| 27. |
Pignatelli F, Nacucchi A, Niro A, et al. Intravitreal dexamethasone implant at the time of silicon oil removal to treat persistent macular edema after rhegmatogenous retinal detachment repair[J/OL]. J Clin Med, 2023, 12(4): 1697[2023-02-20]. https://pubmed.ncbi.nlm.nih.gov/36836233/. DOI: 10.3390/jcm12041697.
|
| 28. |
Altun A, Kanar HS, Aki SF, et al. Effectiveness and safety of coadministration of intravitreal dexamethasone implant and silicone oil endotamponade for proliferative diabetic retinopathy with tractional diabetic macular edema[J]. J Ocul Pharmacol Ther, 2021, 37(2): 131-137. DOI: 10.1089/jop.2020.0079.
|
| 29. |
Khan Z, Kuriakose RK, Khan M, et al. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications[J]. Ophthalmic Surg Lasers Imaging Retina, 2017, 48(2): 160-166. DOI: 10.3928/23258160-20170130-10.
|
| 30. |
Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant[J]. Retina, 2014, 34(4): 719-724. DOI: 10.1097/IAE.0b013e3182a48958.
|
| 31. |
Zhioua I, Semoun O, Lalloum F, et al. Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema[J]. Retina, 2015, 35(7): 1429-1435. DOI: 10.1097/IAE.0000000000000490.
|
| 32. |
Parisi G, Fallico M, Avitabile T, et al. Intravitreal dexamethasone implant for postoperative macular oedema secondary to vitrectomy for epiretinal membrane and retinal detachment: a systematic review and meta-analysis[J/OL]. J Ophthalmol, 2021, 2021: 6627677[2021-04-16]. https://pubmed.ncbi.nlm.nih.gov/33953965/. DOI: 10.1155/2021/6627677.
|
| 33. |
Furino C, Boscia F, Recchimurzo N, et al. Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker[J]. Retina, 2014, 34(8): 1612-1616. DOI: 10.1097/IAE.0000000000000105.
|
| 34. |
陳志杰, 劉法, 劉江. 糖尿病黃斑水腫患者地塞米松玻璃體腔植入劑治療后繼發眼壓升高的影響因素分析[J]. 中華眼底病雜志, 2023, 39(6): 459-463. DOI: 10.3760/cma.j.cn511434-20230104-00007.Chen ZJ, Liu F, Liu J. Factor analysis of secondary intraocular hypertension after intravitreal dexamethasone implantation in patients with diabetic macular edema[J]. Chin J Ocul Fundus Dis, 2023, 39(6): 459-463. DOI: 10.3760/cma.j.cn511434-20230104-00007.
|